{"id":80118,"date":"2025-09-23T03:48:12","date_gmt":"2025-09-23T03:48:12","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/80118\/"},"modified":"2025-09-23T03:48:12","modified_gmt":"2025-09-23T03:48:12","slug":"pfizer-amps-up-push-into-obesity-treatments-with-4-9b-deal-for-metsera","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/80118\/","title":{"rendered":"Pfizer amps up push into obesity treatments with $4.9B deal for Metsera"},"content":{"rendered":"

Pfizer is doubling down on obesity treatments<\/a> by spending $4.9 billion on the development-stage drugmaker Metsera.<\/p>\n

The COVID-19 vaccine and treatment maker said early Monday that it will pay $47.50 per share in cash for each Metsera share. That represents a premium of more than 42% to Metsera\u2019s closing price Friday.<\/p>\n

Pfizer also could pay an additional $22.50 per share depending on how Metsera\u2019s product pipeline develops.<\/p>\n

Metsera has no products on the market, but its pipeline includes four programs in clinical development and one in mid-stage testing.<\/p>\n

Demand for obesity treatments<\/a> has soared in recent years, fueled by market leaders Zepbound from Eli Lilly and Wegovy from Novo Nordisk.<\/p>\n

Pfizer currently has no obesity treatments on the market but has some in clinical development. Earlier this year, the company said it was ending development of a potential once-daily pill treatment before it started late-stage testing, the biggest and most expensive phase of clinical development.<\/p>\n

Shares of Pfizer Inc., based in New York, climbed 31 cents to $24.33 before markets opened Monday while Metsera’s stock advanced about 60%.<\/p>\n","protected":false},"excerpt":{"rendered":"Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera. The COVID-19…\n","protected":false},"author":2,"featured_media":80119,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[53802,584,79,160,18,3334,135,475,3955,474,19,42803,17,462,7176,4077],"class_list":{"0":"post-80118","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-53802","9":"tag-article","10":"tag-business","11":"tag-coronavirus","12":"tag-eire","13":"tag-general-news","14":"tag-health","15":"tag-health-care","16":"tag-health-care-costs","17":"tag-healthcare","18":"tag-ie","19":"tag-immunizations","20":"tag-ireland","21":"tag-medication","22":"tag-obesity","23":"tag-u-s-news"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/80118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=80118"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/80118\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/80119"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=80118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=80118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=80118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}